Ionis announced long-term data for Dawnzera for hereditary angioedema, or HAE, presented at the 2025 American College of Allergy, Asthma & Immunology, or ACAAI, Annual Scientific Meeting. Results demonstrate the long-term durability and safety of Dawnzera. At one year in the OASISplus open-label extension study, Dawnzera demonstrated a 94% overall mean HAE attack rate reduction. In a separate switch cohort, patients who switched to Dawnzera from lanadelumab, C1-esterase inhibity, or berotralstat experienced a 68% improvement in monthly HAE attack rate compared to their prior prophylactic therapy.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Ionis Pharmaceuticals price target raised to $77 from $70 at Piper Sandler
- Ionis Pharmaceuticals Faces Investor Risks Amid Market Volatility and Milestone Uncertainties
- Ionis Pharmaceuticals price target raised to $100 from $95 at H.C. Wainwright
- Ionis Pharmaceuticals price target raised to $94 from $90 at Morgan Stanley
- Ionis Pharmaceuticals price target raised to $99 from $59 at TD Cowen